Risk assessment and primary prevention of CVD
The UKCPA/JOMO study day has become the main event in the respiratory pharmacy calendar. Despite the challenges this year this speakers and sessions were excellent.
NHS attendee at the UKCPA/JOMO respiratory study day
|Satellite||Risk assessment and primary prevention of CVD|
|Speakers||Sadeer Fhadil (Highly Specialist Cardiac Pharmacist - Cardiac Pharmacy Department, Barts Heart Centre, Barts Health NHS Trust)|
This talk will assess the impact of cardiovascular disease, discussing who to target and when. It will discuss various cardiovascular risk assessment tools and how to manage those at risk. Management will focus on key areas for CVD prevention; Atrial fibrillation, blood pressure and cholesterol, including non-pharmacological interventions. We will also discuss the controversial role of aspirin in primary prevention of CVD and review the evidence.